Objective: The aim of this prospective study was to evaluate the efficacy of transarterial chemoembolization using miriplatin, a platinum-based anticancer drug, as a retreatment regimen for hepatocellular carcinoma (HCC) unresponsive to chemoembolization using epirubicin. Methods: Between April 2013 and December 2014, we enrolled 57 consecutive chamoembolization-naïve patients with unresectable HCC, and performed chemoembolization with epirubicin. Treatment effect, necrotizing rate of the target nodules, was evaluated at 1-3 months after treatment using contrast-enhanced CT or MRI. We subsequently included retreatment chemoembolization with miriplatin for patients whose treatment effect was <50% after chemoembolization with epirubicin. The treatment effect after chemoembolization with miriplatin and the liver function before and after chemoembolization were evaluated. Results: Eighteen patients of the 57 showed a treatment effect <50% after chemoembolization with epirubicin, and were switched to chemoembolization with miriplatin. The treatment effect after chemoembolization with miriplatin was ≥50% in four (22%) patients. Four of the remaining 14 (78%) patients who had <50% necrosis exhibited deterioration of the liver function after chemoembolization with miriplatin. Univariate analysis indicated that an alpha-fetprotein-L3 level <10% and a serum albumin level ≥3.6 g/dl were predictive factors of therapeutic response after chemoembolization with miriplatin (P < 0.05). However, there was no predictive factor regarding the deterioration of liver function after chemoembolization with miriplatin. Conclusions: In unresectable HCC patients who were unresponsive to chemoembolization with epirubicin, switching the chemotherapeutic regimen to a platinum-based anticancer drug in retreatment chemoembolization should be considered as a treatment option. Trial registration: UMIN 000015887
Introduction
Transarterial chemoembolization (TACE) is recommended for patients with intermediate-stage hepatocellular carcinoma (HCC) (1) . The rationale for TACE is that the intra-arterial infusion of cytotoxic agents followed by embolization of the tumor-feeding blood vessels will result in strong cytotoxic and ischemic effects. The survival benefit of TACE has been confirmed in two randomized controlled trials (2, 3) and a meta-analysis (4) . Conventional TACE is performed using an emulsion of a chemotherapeutical drug combined with iodized oil (Lipiodol: Guerbet, Aulnay-Sous-Bois, France) as the drug carrier. As chemotherapeutic agents in TACE, epirubicin, doxorubicin, mitomycin C, carboplatin and cisplatin are administered in a clinical setting. Recently, a new platinum-based anticancer agent, miriplatin (Miripla: Dainippon Sumitomo Pharma, Osaka, Japan) was developed for TACE treatment for HCC (5) . Miriplatin is a lipophilic platinum complex that contains myristates as leaving groups and diaminocyclohexane as a carrier ligand. Intraarterial administered miriplatin is associated with less hepatic arterial damage than zinostatin stimalamer or epirubicin (6, 7) . However, there are no generally accepted standards in the choice of chemotherapeutical drug and dose adaptation. Moreover, to our knowledge, there have only been a few retrospective studies regarding the efficacy of TACE involving the switching of chemotherapeutic agents (8) (9) (10) . The present prospective study was carried out to evaluate the safety and efficacy of retreatment TACE with switching of the drug to miriplatin (miriplatin-TACE) in patients with HCC unresponsive to initial TACE with epirubicin (epirubicin-TACE).
Patients and methods

Study setting and design
This prospective, cohort study was conducted between April 2013 and December 2014 at a single center. The study protocol was approved by the institutional ethics committee (approval number: 25-32) and complied in compliance with local laws and the Declaration of Helsinki. All patients provided written informed consent before enrollment.
Inclusion criteria
The inclusion criteria for this study were as follows: (1) HCC diagnosis was confirmed pathologically and/or by positive imaging findings (using at least two imaging modalities) (1); (2) no indication of either surgical resection and percutaneous ablation therapies (i.e. patients did not meet the following criteria: ≤3 nodules of ≤3 cm, no extrahepatic metastasis, no vascular invasion, and good liver function) (11); (3) an Eastern Cooperative Oncology Group performance status score of 0-1; (4) at least one measurable intrahepatic tumor that was staged using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI); (5) no evidence of portal vein or other venous thrombosis, extrahepatic metastasis, or uncontrollable ascites; (6) Child-Pugh class A or B; (7) adequate hepatic function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] levels <5 times the upper limit of the normal range, a serum bilirubin level <3 mg/dl, and a serum albumin level >2.0 g/dl); (8) adequate renal function (serum creatinine <1.5 times the upper limit of the normal range) and (9) no history of the use of platinum-based anticancer drugs. Ninety-one consecutive patients with HCC were screened, and 57 of the 91 were enrolled and received epirubicin-TACE.
TACE procedure
We introduced a 3-F coaxial microcatheter into a segmental of the subsegmental branch of the hepatic artery that supplied the target HCC and then injected the chemotherapeutic agents, including epirubicin hydrochloride (Farmorubicin: Pharmacia and Upjohn, Tokyo, Japan) as initial TACE or miriplatin as retreatment TACE. First, 50 mg of epirubicin with a mixture of 5 ml of iodized oil and 5 ml of distilled water, or 120 mg of miriplatin in solution with 6 ml of iodized oil were prepared. Then, the mixture (or the solution) was injected until it entered the intrahepatic branch of the portal vein or exhibited stasis. This procedure was followed by embolization using a gelatin sponge (1 mm × 1 mm × 1 mm) (Gelpart: Nippon Kayaku, Tokyo, Japan).
Assessments
The primary outcome was the therapeutic response to retreatment TACE with miriplatin in patients who were unresponsive to initial TACE with epirubicin. The secondary outcome was assessment of adverse events after retreatment TACE with miriplatin. Treatment response was evaluated using contrast-enhanced CT or MRI obtained in 1-3 months after TACE, according to the Response Evaluation Criteria in Cancer of the Liver (RECICL) (12) by two radiologists who were independent of the author group. In RECICL, treatment effects (TE) regarding the target nodules were classified as follows: TE4, 100% tumor necrosis or a reduction in tumor size; TE3, 50-100% tumor necrosis or a reduction in tumor size, TE2, proportion of tumor necrosis is higher than in TE1 but lower than TE3; TE1, >25% increase in tumor size. Patients achieving TE4 after their initial TACE were followed up without further treatment. In patients with TE3, we performed TACE treatment repeatedly without switching the anticancer drug (i.e. epirubicin-TACE); we performed retreatment TACE with switching of the anticancer drug (i.e. miriplatin-TACE) in patients with TE1 or TE2 after initial TACE (Fig. 1) .
Adverse events were assessed according to the National Cancer Institute-Common Terminology Criteria for Adverse Effects (NCI-CTCAE), version 3.0 (http://ctep.cancer.gov/reporting/ctc.html). Hematological toxicity was evaluated by measuring the number of leukocytes and thrombocytes, and AST, ALT, albumin, total bilirubin, creatinine and prothrombin activity within 1 week before, and two or three times during the first 7 days after TACE, and at 1 month after TACE.
Statistical analysis
We set the sample size at n = 18, which was required to yield a oneside alpha value of 5% and power of 90%, with an expected response rate of 22% (8), and threshold response rate of 2%, based on reported response to sorafenib treatment which has been a standard treatment for patients who do not respond to TACE (13) .
Continuous variables were expressed as mean ± SD or median with ranges, and categorical variables were expressed as counts with percentages. The categorical differences were analyzed using the Fisher's exact or χ 2 test. Thirteen variables concerning treatment response after retreatment TACE were determined using univariate analysis. They were: age (<75 years vs. ≥75 years); gender (male vs. female); background liver disease (hepatitis C virus infection vs. others); Child-Pugh class (A vs. B); diameter of the largest tumor (<70 mm vs. ≥70 mm); number of tumors (<6 vs. ≥6); ascites (present vs. absent); albumin (<3.6 mg/dl vs. ≥3.6 mg/dl); total bilirubin (<1.1 mg/dl vs. ≥1.1 mg/dl); ALT (<49 IU/L vs. ≥49 IU/L); alphafetoprotein (AFP; ≤20 ng/ml vs. >20 ng/ml); Lens culinaris agglutininreactive fraction of AFP (AFP-L3; <10% vs. ≥10%); and protein induced vitamin K absence/antagonist-II (PIVKA-II; < 40 mAU/ml vs. ≥40 mAU/ml). The cut-off diameter for the largest tumor was determined to be 70 mm through univariate analyses of hypothetical cutoff levels set at 10-mm intervals. Multivariate analysis was carried out on the significant (P values < 0.05) variables using the logistic regression model. In all the analyses, P values < 0.05 were regarded as statistically significant. Statistical analyses were performed using SPSS version 23 software for Windows (IBM SPSS, Chicago, IL, USA).
Results
Patient characteristics
The backgrounds of a total of 57 patients who were enrolled in this study are detailed in Table 1 . Their mean age was 74 years, and 40 (70%) had Child-Pugh class A liver function; the remaining 17 (30%) had Child-Pugh class B liver function.
Outcomes
Of the 57 enrolled patients who initially received TACE with epirubicin, 11 (19%) who were evaluated as TE4 had no additional retreatments planned; 13 (23%) who were evaluated as TE3 were planned to receive treatment with repeat TACE using the same drug (i.e. epirubicin); and 18 (32%) evaluated as TE2 or TE1 were planned to receive retreatment with TACE with miriplatin 2 or 3 months later. The remaining 15 (26%) patients did not fit with the inclusion criteria and were excluded from the protocol, including those who intended to undergo other treatments (n = 4), withdrew consent (n = 4), had symptomatic progression (n = 4) or were lost to follow-up (n = 3) (Fig. 1) . We evaluated therapeutic efficacy and liver function in the 18 patients who underwent retreatment TACE with miriplatin. The background characteristics of the 18 patients are detailed in Table 1 . The mean age of the patients was 71 years; 66% had Child-Pugh class A liver function and 34% had Child-Pugh class B liver function. Of these 18 patients, four (22%) achieved TE3. In the remaining 14 patients, 10 (56%) and four (22%) achieved TE2 and TE1, respectively. Table 2 details the incidences of the adverse events related to initial TACE with epirubicin and retreatment TACE with miriplatin. Two (11%) and four (22%) patients had Grade 3 AST elevations that recovered to the normal range within 1 week without additional treatment after initial TACE with epirubicin and retreatment TACE with miriplatin, respectively. The liver function evaluated using the Child-Pugh score did not change in the four patients who had TE3; and the liver function worsened in four of the 14 patients who had TE1 or TE2. There were no significant factors that predicted the deterioration of the liver function after retreatment TACE with miriplatin in univariate analysis.
Adverse events
Predictive factors for the response to retreatment TACE with miriplatin
Univariate analysis of the pretreatment factors affecting treatment response to retreatment TACE revealed that a serum albumin level ≥3.6 g/dl and a serum AFP-L3 < 10% were significant predictive factors (Table 3) . However, multivariate analysis of the abovementioned two pretreatment factors indicated that they were not significant predictive factors (P = 0.189 for a serum albumin level ≥3.6 g/dl and P = 0.206 for a serum AFP-L3 < 10%).
Discussion
In the current study, 32% of the enrolled patients were unresponsive; that is, the TE was <50% after initial TACE with epirubicin, and these unresponsive cases were switched to retreatment TACE with miriplatin. After TACE with miriplatin, 22% of patients exhibited a tumor response (i.e. TE > 50%). Univariate analysis showed that AFP-L3 level <10% and serum albumin level ≥3.6 g/dl were found to be predictive factors of response to retreatment TACE, although multivariate analysis found no significant predictors of response to retreatment TACE. This data suggest that in patients who were unresponsive to initial TACE with epirubicin, switching the chemotherapeutic regimen to a platinum-based anticancer drug in retreatment TACE might be worth considering. Hepatic artery obstruction induces ischemic tumor necrosis with a high rate of objective responses in patients with HCC (14) . Hepatic artery obstruction is known as transarterial embolization (TAE); and TAE combined with a prior injection into the hepatic artery of chemotherapeutic agents is known as TACE, and the most common approach is to inject adriamycin or cisplatin (15) . However, the best chemotherapeutic agents and the ideal retreatment regimen for TACE have not yet been established. Previous retrospective studies have indicated that switching the chemotherapeutic agents from epirubicin to cisplatin was effective as salvage retreatment TACE in patients who were unresponsive to initial TACE (8) (9) (10) . The response rate of retreatment TACE with switching the agents has been variously reported as 22% (8), 27.5% (9) and 40% (10), although the TACE techniques and embolic agents used were different; switching the regimen to carboplatin or cisplatin (8) and cisplatin powder (9, 10) , microsphere as for an embolic agent (10) . Concerning these studies, switching the chemotherapeutic agent from epirubicin to cisplatin might be a feasible option for the patients who were resistant to the initial regimen of TACE. On the other hand, some patients who were unresponsive to initial TACE had objective responses after retreatment TACE without switching the chemotherapeutic agents (16) .
The current study showed that miriplatin-TACE was safe and well tolerated as a retreatment regimen after initial epirubicin-TACE. Liver function determined as Child-Pugh score after miriplatin-TACE worsened in four patients. We hypothesized that decreased liver function after the retreatment TACE was mainly caused by tumor progression, because these four patients could not obtain tumor responses after the two TACE treatments. However, whether or not further repeated TACE with miriplatin could worsen their liver function is an unresolved issue. Patient selection for retreatment TACE could be a complicated problem because TACE can be a double-edge sword, independent from the presence of objective response, if deterioration of liver function is caused by the intervention; this may obviate any kind of further treatment and trigger liver-related death (17) . The optimal retreatment decisions should not only be taken based on target lesion responses, but also on changes in liver function following TACE (18) . Most previous studies have reported the absence of an objective radiological response after two TACE cycles as a sign of TACE failure (19, 20) . Deterioration of liver function following TACE has been either not specified, or has previously been mentioned as a criterion of TACE failure by several expert groups (17, 21, 22) . Unfortunately, the current study could not determine significant predictive factors associated with the deterioration of liver function following retreatment TACE. At present, the overall success of TACE might depend on careful retreatment decisions before TACE.
The present study had several limitations, including the small number of patients enrolled from a single institute; this created the potential for selection and technical bias. Only the TE was evaluated as the study endpoint after retreatment TACE in the current study. It is preferable to evaluate additional outcomes, such as time to progression and overall survival, to confirm the TACE response, although anti-tumor response might be a surrogate marker for overall survival (23) . Unfortunately, the relatively short follow-up periods prevented full investigation of these outcomes. In addition, comparisons of the other switching regimens, such as miriplatin to epirubicin, and epirubicin to cisplatin, should be evaluated in future trials. Furthermore, in this study, we judged each patient's follow-up plan according to the response evaluated after the one TACE session. This fixed schedule concerning the response evaluations might be one of the limitations of the current study, as some advanced HCC patients are not expected to be treated completely in one TACE session because of the tumor size and/or the tumor number. In on-demand TACE treatments, including the current study, the response evaluation schedules might be essential to improving survival (19) . Despite these limitations, this prospective cohort study showed that switching the chemotherapeutic agent to miriplatin in retreatment TACE had the potential for an additional tumor response in HCC patients unresponsive to initial TACE with epirubicin.
